News and Updates

The FDA has cleared Fate Therapeutics’ FT839 for clinical trials. Discover how this off-the-shelf CAR-T therapy aims to revolutionize autoimmune treatment.

Discover three psychedelic medicine companies nearing critical clinical trial data that could reshape mental health treatment and attract investor interest.

AstraZeneca’s Wainua fails to meet primary endpoints in the CARDIO-TTRansform heart disease trial, prompting expert scrutiny over study design and efficacy.

New Phase 2 trial results for tralokinumab show promising safety and pharmacokinetics for children suffering from moderate-to-severe atopic dermatitis.

NASA prepares for a landmark ISS mission featuring Dr. Anil Menon. Discover how this physician-astronaut is advancing the future of space medicine.

A new clinical trial confirms stem cell transplants for Parkinson's are safe and feasible, marking a major milestone in regenerative neurological medicine.

AstraZeneca and Ionis face a setback as their investigational heart drug misses primary endpoints in a Phase 3 trial. Discover what this means for patients.

AstraZeneca and Ionis face a setback as their ATTR-CM drug trial misses primary goals. See why analysts believe the market reaction may be an over-reaction.

New peer-reviewed data confirms the efficacy and safety of Yesafili in treating Diabetic Macular Edema, offering a robust biosimilar option for patients.

Regulators have ordered the withdrawal of an Amgen drug after evidence of data manipulation, highlighting critical lapses in clinical trial integrity.